Acquisitions11 Mar 2025, 12:15 am
Syngene Acquires its First Manufacturing Facility in the US, Expanding Global Biologics Footprint
AI Summary
Syngene International Limited, a global contract research, development, and manufacturing organization (CRDMO), has announced the acquisition of its first biologics site in the USA. The state-of-the-art biologics facility, acquired by Syngene USA Inc., will expand Syngene’s total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services. The investment is expected to create jobs, stimulate local economic activity, and strengthen domestic biologics manufacturing capabilities, while also contributing to pharmaceutical innovation and supply chain resilience.
Key Highlights
- Syngene acquires its first biologics site in the USA, expanding its global biologics footprint.
- The acquisition increases Syngene’s total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services.
- The investment is expected to create jobs and stimulate local economic activity, strengthening domestic biologics manufacturing capabilities.
- The new facility will provide Syngene’s customers with continuity of supply from its four development and manufacturing facilities located in India and North America.
- The investment highlights the potential for deeper economic collaboration between India and the United States.